Dipeptidyl peptidase IV inhibition
1 article · search the full text for this term
-
Dipeptidyl peptidase-IV (DPP-IV) Inhibitors – a promising oral anti-diabetic drug
Abstract: Dipeptidyl-peptidase IV (DPP-4) inhibitors inhibit the degradation of the incretins i.e glucagon-like peptide1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). Incretins augment the insulin release by a blood glucose-dependent mechanism. Generally DPP-IV enzyme is responsible for inactivating incretins and this enzyme inhibition will prolong and enhance the activity of GLP-1 and GIP. DPP-IV inhibitors increase post prandial insulin secretion, decreases glucagon secretion and seems to have beneficial effect on cardiovascular system, …
Published in Research and Reviews: A Journal of Pharmaceutical Science · Vol. 11, Issue 3, 2020 · pp. 1–6 Read article